Best Diagnostics Stocks for December 2025 Based on 5-Year CAGR: Dr Agarwal’s, Artemis and More

India’s diagnostics and healthcare services sector continues to expand, supported by rising medical infrastructure and growing testing demand. Increased patient awareness and adoption of preventive care have strengthened the industry outlook.

Companies with strong return ratios, manageable leverage and multi-year performance remain well-positioned in this evolving space. The stocks listed below reflect healthy profitability and long-term compounding strength.

Top Diagnostics Stocks for December 2025 by 5-Year CAGR

Broader Fundamentals

• Dr Agarwal’s Eye Hospital combines a 29.50% ROE with a market cap of ₹2,656.58 crore and a P/E of 42.19. Its dividend yield of 0.11% indicates a growth-focused approach.
• Artemis Medicare Services has delivered 68.71% returns over five years, supported by a P/E of 43.74 and steady ROE of 12.92%.
• Indraprastha Medical offers a 0.91% dividend yield alongside strong profitability and low leverage.
• Max Healthcare Institute, with a market cap of ₹1,05,384.72 crore, reflects scale and operational consistency despite a higher P/E of 74.79. Its 50.71% 5-year return underscores sustained demand for healthcare services.
• Vimta Labs stands out for its near-zero debt and 25.21% ROCE, supported by a market cap of ₹2,711.16 crore and a P/E of 36.32. These metrics highlight resilience and growth potential across the listed companies.

Top Diagnostics Stocks for December 2025 by 1-Year Return

Sector Outlook

The diagnostics and healthcare services sector benefits from structural drivers such as rising lifestyle diseases and increased preventive testing. Digital adoption and home-based diagnostics are expanding market reach. Companies with strong governance, efficient capital usage and diversified service offerings are expected to maintain growth momentum. Investors continue to monitor regulatory developments and pricing trends in this high-growth segment.

Read More: Best Debt-Free Stocks for December 2025 Based on 5-Year CAGR.

Conclusion

Diagnostics and healthcare service stocks remain attractive for long-term investors due to strong fundamentals and sector tailwinds. Companies like Dr Agarwal’s Eye Hospital and Indraprastha Medical lead on profitability and efficiency metrics.

Artemis Medicare, Max Healthcare and Vimta Labs offer balanced growth supported by manageable leverage and consistent returns. The sector’s outlook remains positive, driven by rising demand and technological advancements.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.